Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction

Toxins (Basel). 2016 Mar 18;8(3):81. doi: 10.3390/toxins8030081.

Abstract

Bladder drug delivery via catheter instillation is a widely used treatment for recurrence of superficial bladder cancer. Intravesical instillation of liposomal botulinum toxin has recently shown promise in the treatment of overactive bladder and interstitial cystitis/bladder pain syndrome, and studies of liposomal tacrolimus instillations show promise in the treatment of hemorrhagic cystitis. Liposomes are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core that can encapsulate hydrophilic and hydrophobic drug molecules to be delivered to cells via endocytosis. This review will present new developments on instillations of liposomes and liposome-encapsulated drugs into the urinary bladder for treating lower urinary tract dysfunction.

Keywords: bladder; botulinum toxin; interstitial cystitis; liposome; overactive bladder.

Publication types

  • Review

MeSH terms

  • Administration, Intravesical
  • Animals
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / therapeutic use
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / therapeutic use
  • Liposomes
  • Neurotoxins / administration & dosage*
  • Neurotoxins / therapeutic use
  • Tacrolimus / administration & dosage*
  • Tacrolimus / therapeutic use
  • Urinary Bladder Diseases / drug therapy*
  • Urinary Bladder Diseases / metabolism
  • Urinary Bladder Diseases / pathology
  • Urothelium / metabolism
  • Urothelium / pathology

Substances

  • Immunosuppressive Agents
  • Liposomes
  • Neurotoxins
  • Botulinum Toxins, Type A
  • Tacrolimus